Skip to main content
Top
Published in: Pathology & Oncology Research 3/2008

01-09-2008 | Original Paper

Systemic Dissemination in Cancer of Unknown Primary is Independent of Mutational Inactivation of the KiSS-1 Metastasis-suppressor Gene

Authors: L. Dova, V. Golfinopoulos, G. Pentheroudakis, I. Georgiou, N. Pavlidis

Published in: Pathology & Oncology Research | Issue 3/2008

Login to get access

Abstract

Cancer of unknown primary represents a heterogeneous group of malignancies characterised by early systemic dissemination and lack of primary site. KiSS1 is a member of the metastasis-suppressor gene family whose functional role is being investigated in human malignancies. We extracted DNA from 50 paraffin-embedded unknown primary tumors and screened KiSS1 exons III and IV for presence of mutations by means of Single Strand Conformational Polymorphism and direct sequencing. Only one tumor specimen harboured a cytosine to guanine point substitution in base 242 of exon IVa, resulting in a proline to arginine switch at codon 81 of the KiSS1 protein (P81R). The remaining 49 tumors harbored wild-type KiSS1 alleles, indistinguishable from those of peripheral blood lymphocytes of 50 healthy controls. Consequently, the propensity for systemic spread of unknown primary tumors may by due to mutations in genes other than KiSS1 or aberrant epigenetic regulation.
Literature
1.
go back to reference Yoshida BA, Sokoloff M, Welch DR, Rinker-Schaeffer CW (2000) Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 92:1717–1730CrossRefPubMed Yoshida BA, Sokoloff M, Welch DR, Rinker-Schaeffer CW (2000) Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 92:1717–1730CrossRefPubMed
2.
go back to reference West A, Vojta PJ, Welch DR, Weissman BE (1998) Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KISS1). Genomics 54:145–148CrossRefPubMed West A, Vojta PJ, Welch DR, Weissman BE (1998) Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KISS1). Genomics 54:145–148CrossRefPubMed
3.
go back to reference Nash KT, Welch DR (2006) The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front Biosci 11:647–659CrossRefPubMed Nash KT, Welch DR (2006) The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front Biosci 11:647–659CrossRefPubMed
4.
go back to reference Pentheroudakis G, Kostadima L, Dova L, Malamou-Mitsi V, Georgiou I et al (2006) The missing kiss of life: Analysis of mutation and protein expression of the metastasis-suppressor gene KISS1 in early breast cancer. Ann Oncol 17(Suppl 9):ix59(101P) Pentheroudakis G, Kostadima L, Dova L, Malamou-Mitsi V, Georgiou I et al (2006) The missing kiss of life: Analysis of mutation and protein expression of the metastasis-suppressor gene KISS1 in early breast cancer. Ann Oncol 17(Suppl 9):ix59(101P)
5.
go back to reference Pentheroudakis G, Briasoulis E, Pavlidis N (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12:418–425CrossRefPubMed Pentheroudakis G, Briasoulis E, Pavlidis N (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12:418–425CrossRefPubMed
Metadata
Title
Systemic Dissemination in Cancer of Unknown Primary is Independent of Mutational Inactivation of the KiSS-1 Metastasis-suppressor Gene
Authors
L. Dova
V. Golfinopoulos
G. Pentheroudakis
I. Georgiou
N. Pavlidis
Publication date
01-09-2008
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2008
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9024-1

Other articles of this Issue 3/2008

Pathology & Oncology Research 3/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine